Á¶Á÷ÆǸ·À» ÀÌ¿ëÇÑ ´ëµ¿¸ÆÆǸ·Ä¡È¯¼úÀÇ Á߱⼺Àû
Midterm Results of Aortic Valve Replacement Using Tissue Valve

´ëÇÑÈäºÎ¿Ü°úÇÐȸÁö 2010³â 43±Ç 6È£ p.627 ~ p.634

¹®´öȯ(Moon Duk-Hwan) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼­¿ï¾Æ»êº´¿ø ÈäºÎ¿Ü°ú
ÀÌÀç¿ø(Lee Jae-Won) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼­¿ï¾Æ»êº´¿ø ÈäºÎ¿Ü°úÇб³½Ç
±èÀ±¼®(Kim Yun-Seok) - ±¹±ºÇÔÆòº´¿ø ÈäºÎ¿Ü°ú
Á¶¿øö(Cho Won-Chul) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼­¿ï¾Æ»êº´¿ø ÈäºÎ¿Ü°ú
Á¤¼ºÈ£(Jung Sung-Ho) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼­¿ï¾Æ»êº´¿ø ÈäºÎ¿Ü°úÇб³½Ç
ÁÖ¼®Áß(Choo Suk-Jung) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼­¿ï¾Æ»êº´¿ø ÈäºÎ¿Ü°úÇб³½Ç
Á¤Ã¶Çö(Chung Cheol-Hyun) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼­¿ï¾Æ»êº´¿ø ÈäºÎ¿Ü°úÇб³½Ç

Abstract

¹è°æ: Á¶Á÷ÆǸ·ÀÇ ³»±¸¼ºÀº ½ÉÀå ÆǸ· ¼ö¼ú¿¡¼­ ±â°èÆǸ·°ú Á¶Á÷ÆǸ·À» ¼±ÅÃÇÏ´Â Áß¿äÇÑ ±âÁØÀÌ µÈ ´Ù. º» ¿¬±¸´Â Á¶Á÷ÆǸ·ÀÌ »ç¿ëµÈ ´ëµ¿¸ÆÆǸ·Ä¡È¯¼úÀÇ Á߱⼺ÀûÀ» ºÐ¼®ÇØ º¸¾Ò´Ù.

´ë»ó ¹× ¹æ¹ý: ÀÌ ¿¬±¸´Â 1990³â 3¿ùºÎÅÍ 2009³â 3¿ù±îÁö Á¶Á÷ÆǸ·À» ÀÌ¿ëÇÏ¿© ´ëµ¿¸ÆÆǸ·Ä¡È¯¼úÀ» ½ÃÇàÇÑ 380¸íÀÇ È¯ÀÚµéÀ» ´ë»óÀ¸·Î ÇÏ¿´´Ù. ¼ú ÈÄ Æò±Õ °üÂû ±â°£Àº 46.7¡¾40.8°³¿ù(0¡­196°³¿ù)À̾úÀ¸¸ç ¿Ü·¡ °æ°ú ±â·Ï°ú Àǹ«±â·ÏÀ» ÅëÇÏ¿© ÈÄÇâÀûÀ¸·Î ºÐ¼®ÇÏ¿´´Ù.

°á°ú: ÃÑ 380¸íÀÇ È¯ÀÚ¿¡¼­ 389¿¹ÀÇ ¼ö¼úÀÌ ½ÃÇà µÇ¾úÀ¸¸ç ȯÀÚµéÀÇ Æò±Õ ¿¬·ÉÀº 69¡¾9¼¼, ³²³à ºñ´Â 227£º162¿´´Ù Á¶±â »ç¸ÁÀº 15¸í(3.9%)À̾ú´Ù. 1 ³â, 5³â, 10³â »ýÁ¸À²Àº 92.3%, 78.1%, 54.2%¿´´Ù. Àç¼ö¼úÀÇ 1³â, 5³â, 10³â ȸÇÇÀ²(Freedom from reoperation)Àº 98.4%, 97.1%, 91.7%¿´À¸¸ç ±¸Á¶Àû ÆǸ· ¼Õ»ó 1³â, 5³â, 10³âÀÇ È¸ÇÇÀ²(Freedom from structural valvular deterioration)Àº 96.1%, 92.3%, 88.0%¿´´Ù. ¼ö¼ú Àü À§ÇèÀÎÀÚÀÇ ´Ùº¯·® ºÐ¼®¿¡¼­ ÀþÀº ³ªÀÌ(p£¼0.001)°¡ Àç¼ö¼úÀÇ À§ÇèÀÎÀÚ¿´À¸¸ç ¼ö¼ú ÈÄ ÆǸ· ºÎÇÏ ÃÖ°í¼Óµµ(p=0.034)¿Í ÀþÀº ³ªÀÌ (p=0.029)°¡ ±¸Á¶Àû ÆǸ· ¼Õ»óÀÇ À§ÇèÀÎÀÚ¿´´Ù. °í·É(p=0.001), Àå½Ã°£ÀÇ ½ÉÆó±â»ç¿ë(long bypass time) (p=0.035), °ü»óµ¿¸Æ ¿ìȸ¼úÀ» µ¿½Ã¿¡ ½Ç½ÃÇÑ °æ¿ì(concomitant CABG) (p=0.003), ¼ú Àü Áߵ ÀÌ»óÀÇ ÁÂ½É½Ç ±â´ÉºÎÀü(Left ventricular ejection fraction, LVEF£¼40%) (p=0.003)ÀÌ Á¶±â »ç¸ÁÀÇ À§ ÇèÀÎÀÚ¿´À¸¸ç ¼ú Àü ½Å±â´ÉÀúÇÏ(estimated glomerular filtration rate, eGFR£¼60 mL/min) (p=0.025)¿Í Áö¼ÓÀûÀÎ Á½ɽǺñ´ë(persistent left ventricular hypertrophy, LVH) (p=0.032)°¡ ¸¸±â »ç¸ÁÀÇ À§ÇèÀÎÀÚ ¿´´Ù.

°á·Ð: ÀÌ ¿¬±¸¸¦ ÅëÇØ Á¶Á÷ÆǸ·À» ÀÌ¿ëÇÑ ´ëµ¿¸ÆÆǸ·Ä¡È¯¼úÀº Àç¼ö¼ú°ú ±¸Á¶Àû ÆǸ· ¼Õ»ó ȸÇÇ À² µîÀÇ Ãø¸é¿¡¼­ ¸¸Á·ÇÒ ¸¸ÇÏ´Ù°í ÇÒ ¼ö ÀÖÀ¸¸ç, ÇâÈÄ ´õ ¸¹Àº ȯÀÚ¿¡¼­ º¸´Ù Àå±âÀûÀÎ ¿¬±¸°¡ ÇÊ¿ä ÇÒ °ÍÀ¸·Î »ý°¢µÈ´Ù.
Background: The durability of the tissue valve is important in choice between a mechanical valve and a tissue valve in cardiac surgery. We studied the mid-term results of tissue valve in the aortic position.

Material and Method: The subjects were 380 patients who had undergone aortic prosthesis replacement between May 1990 and March 2009. We retrospectively analyzed hospital and outpatient records: the mean age was 69¡¾9 years; the male to female ratio was 227£º162; and the mean follow-up duration was 46.7¡¾40.8 months (range 0¡­196 months).

Result: 389 surgical cases in total had been taken with 380 patients. Early death occurred in 15 patients (3.9%). Overall survival rate at 1, 5 and 10 years were 92.3%, 78.1% and 54.2% respectively. Freedom from reoperation at 1, 5 and 10 years were 98.4%, 97.1% and 91.7% respectively. Freedom from structural valvular deterioration at 1, 5 and 10 years were 96.1%, 92.3% and 88.0% respectively. In the multivariate analysis of preoperative risk factors, young age (p£¼0.001) was significant risk factor for reoperation. High peak velocity in the postoperative period (p=0.034) and young age (p=0.029) were significant risk factors for structural valvular deterioration. Old age (p=0.001), long bypass time (p=0.035), concomitant coronary artery bypass graft surgery (p=0.003) and preoperative low left ventricular ejection fraction (p=0.003) were significant factors for early mortality. Preoperative estimated glomerular filtration rate (£¼60 mL/min) (p=0.025) and persistent left ventricular hypertrophy (p=0.032) were the risk factors for late mortality.

Conclusion: This study showed that the freedom from reoperation and the freedom from structural valvular deterioration in aortic tissue valve replacement were acceptable. It will be necessary to conduct further studies with long-term follow-up and more patients.

Å°¿öµå

´ëµ¿¸Æ ÆǸ·, ¼ö¼ú, Á¶Á÷, ÀΰøÆǸ·
Aortic valve, surgery, Tissue, Heart valve prosthesis
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
This study showed that the freedom from reoperation and the freedom from structural valvular deterioration in aortic tissue valve replacement were acceptable; Overall survival rate at 1, 5 and 10 years were 92.3%, 78.1% and 54.2% respectively. Freedom from reoperation at 1, 5 and 10 years were 98.4%, 97.1% and 91.7% respectively.
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå